ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

ClinicalTrials.gov ID: NCT06597344

Public ClinicalTrials.gov record NCT06597344. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b, Open-label, Single-arm Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Study identification

NCT ID
NCT06597344
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
97 participants

Conditions and interventions

Interventions

  • Gepotidacin Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 1, 2024
Primary completion
Mar 9, 2025
Completion
Mar 9, 2025
Last update posted
Feb 10, 2026

2024 – 2025

United States locations

U.S. sites
22
U.S. states
8
U.S. cities
20
Facility City State ZIP Site status
GSK Investigational Site Modesto California 95350-5365
GSK Investigational Site Pasadena California 91101-2453
GSK Investigational Site San Diego California 92120-5259
GSK Investigational Site Valencia California 91355
GSK Investigational Site Miami Florida 33135
GSK Investigational Site Ormond Beach Florida 32174-6302
GSK Investigational Site Palm Springs Florida 33406-7671
GSK Investigational Site Palm Springs Florida 33461
GSK Investigational Site Plant City Florida 33563-4202
GSK Investigational Site Sweetwater Florida 33172-2741
GSK Investigational Site West Palm Beach Florida 33409-3401
GSK Investigational Site West New York New Jersey 07093-2622
GSK Investigational Site New York New York 10016-7313
GSK Investigational Site Dayton Ohio 45424
GSK Investigational Site Forney Texas 75126-4174
GSK Investigational Site Houston Texas 77036
GSK Investigational Site Houston Texas 77087
GSK Investigational Site Kingwood Texas 26537
GSK Investigational Site Mesquite Texas 75149
GSK Investigational Site Missouri City Texas 77459-4756
GSK Investigational Site Bountiful Utah 84010-4943
GSK Investigational Site Morgantown West Virginia 26501

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06597344, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06597344 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →